Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L. Levine, D. Gary Gilliland, Martha Wadleigh et al.|Cancer Cell|2005Cited by 3k
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel‐Wahab, Ross L. Levine, Elisabeth Paietta et al.|Blood|2009Cited by 718
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative NeoplasmsDebra Van Egeren, Sahand Hormoz, Javier Escabi et al.|Cell stem cell|2021Cited by 209
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <i> <scp>FLT</scp> 3 </i> ‐ <scp>ITD</scp> acute myeloid leukaemia in first complete remissionAndrew M. Brunner, Yi‐Bin Chen, Shuli Li et al.|British Journal of Haematology|2016Cited by 174
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S. Garcia, Robert J. Soiffer, Yael Flamand et al.|Blood|2022Cited by 51